Business Wire

CA-JUNIPER-NETWORKS

23.1.2023 09:01:52 CET | Business Wire | Press release

Share
Juniper Networks Chosen to Upgrade Virgin Media O2’s Core IP Backbone Network to 800G Readiness

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Virgin Media O2, one of the UK’s largest fixed and mobile service providers with approximately 50 million online media connections, successfully upgraded its IP core backbone network with Juniper – capable of supporting 800G. Virgin Media O2 is investing in sustainable infrastructure for the long term that can support sustained data growth and bandwidth demands. Its investment underpins the rapid introduction of revenue-generating services while delivering significantly-reduced power, cooling and space consumption and costs.

Consistently good user experience is a fundamental benchmark of success. As its 5G and network expansion continues, Virgin Media O2 turned to Juniper to build a network that is 400G-enabled and 800G-ready to create a near future-proofed digital foundation for its customers. Virgin Media O2 selected Juniper as the technology partner for this strategic upgrade for numerous reasons, including its previous track record as a key networking provider for more than ten years with Virgin Media and O2 before their joint venture in 2021. Another significant factor was Juniper’s ability to deliver compelling economics for Virgin Media O2. These include long-term investment protection through continuous custom silicon innovation by keeping pace with market demands, the planned use of automation tools to help reduce operational costs and a favorable Total Cost of Ownership (TCO) with a reduced energy consumption design.

News Highlights

  • In the past year, Virgin Media O2 has seen 32 percent traffic growth on its mobile network, 16 percent growth in broadband data downloads and a peak traffic load of 22TB, underlining the need for increased data capacity and flexible scalability
  • Virgin Media O2 has successfully migrated all core traffic in its six backbone locations across the UK with Juniper Networks PTX10008 Packet Transport Routers, which are purpose-built to deliver cloud-optimized network transformation at scale and with operational flexibility
  • The modular PTX10008 routers deliver reduced resource consumption as a result of inherently-sustainable design features, including front-to-back cooling, flexible power supplies that can use either high- or low-power modes and high-density port capability that enables optimized throughput in a compact form factor
  • Scalable, secure 400G capability is achieved through ultra-high port density, native inline MACSec encryption on all ports, coupled with the latest generation of ASIC innovation that powers a range of line cards
  • PTX10008 routers support 400G coherent optical transceivers (400G ZR and ZR+) without any density loss today, and are 800G-capable with upgradeability to 800G in the future with silicon innovation and easily-exchanged line cards in the chassis
  • Virgin Media O2’s infrastructure will be underpinned by Juniper’s single operating system, Junos® OS Evolved. This will provide ongoing continuity for streamlined operations.

Supporting Quotes

“Virgin Media O2’s stated ambition is to ‘upgrade the UK’, providing fast, seamless broadband access and mobile services to as many homes and businesses as possible. This calls for responsible, strategic innovation and investment to create an agile network infrastructure that can simultaneously scale in step with our business, be mindful of resource consumption and deliver an extended lifecycle that protects our investment. Juniper is a long-standing technology partner, so it is very reassuring that it has the same vision for sustainable growth, user experience and the fundamental importance of digital enablement in our communities and economy.”

- Jeanie York, Chief Technology Officer, Virgin Media O2

“Service providers face a complex set of technical and commercial challenges that can be contradictory, even intractable—and likely only to multiply in the future—without the right approach. Virgin Media O2 has chosen to leverage silicon, software and automation innovation from Juniper that can turn complexity on its head to deliver a simplified, more reliable and more sustainable network foundation for its business. This means the company can embrace and accelerate growth and service evolution, safe in the knowledge that its millions of users will continue to be able to enjoy the best digital experiences going forward, whatever demands the future may bring.”

- Raj Yavatkar, Chief Technology Officer, Juniper Networks

Additional Information

Juniper’s Climate Change & Sustainability Pages
CEO Blog: Juniper’s Carbon Neutral Pledge
CTO Blog: Sustainable Networking – The Time is Now
Juniper’s 2022 Corporate Sustainability Report

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Statement of Product Direction

The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements.

Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information.

Category - Cloud & Service Provider

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005101/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye